On the year 2006, FDA has finally proposed that over-the-counter transactions should be labelled.

The U.S. Food and Drug Administration (FDA) proposed to amend the labeling regulations on over-the-counter pain relievers. The proposal wanted to include important safety information about the potential for stomach bleeding and liver damage. This is a response to the fact that liver damage because of medicine has been prevalent recently. For products containing acetaminophen, the FDA proposed new warnings highlighting the risk of liver toxicity. The FDA further recommended that the label containing the name of the formula be shown at the box of the medicine that contains this.

November 9, 2006: Perrigo Company Issues Voluntary Recall on Acetaminophen Caplets

When the caplets of this formula were seen to have tiny metals that would be detrimental to the consumers’ liver, the FDA ordered the taking away of the products. Approximately 11 million bottles containing varying quantities of acetaminophen 500 mg caplets are affected by this recall. As of the time of the recall, no illnesses, injuries, or consumer complaints had been reported.

February 3, 2006: Consumer Group Warns About Potentially Fatal Liver Failure

In a posting on its website, national non-profit consumer advocacy Public Citizen writes that acetaminophen is linked to a large increase in cases of potentially fatal liver failure. Since the year 2003, the FDA has been actively advocating to consumers that they should have informed decision in deciding which medicine to take.